ABLYNX WILL ANNOUNCE ITS 2015 FULL YEAR RESULTS WITH WEBCAST ON 25 FEBRUARY 2016

Thursday, February 18, 2016 6:11 AM UTC

GHENT, Belgium, Feb. 18, 2016 -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will announce its full year results for 2015 on Thursday 25 February 2016 at 7.00 am CET.

The Ablynx management team will host a conference call and webcast during which the full year results for 2015 will be presented, followed by a Q&A session. This event will be held on Thursday 25 February 2016 at 4.00 pm CET/10.00 am EST.

The conference call will be webcast live and may be accessed by clicking here. If you would like to participate in the Q&A session, please dial +32(0)2 404 06 62 and use confirmation code 4640794. Shortly after the call, a replay of the webcast and copy of the presentation will be available on the Ablynx website under http://www.ablynx.com/news/events-presentations/.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has approximately 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact Ablynx: Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]

Marieke Vermeersch Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: [email protected]
Follow us on Twitter @AblynxABLX

Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: [email protected]

Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: [email protected]

press release in pd format http://hugin.info/137912/R/1986956/729119.pdf

HUG#1986956

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

ABLYNX WILL ANNOUNCE ITS 2015 FULL YEAR RESULTS WITH WEBCAST ON 25 FEBRUARY 2016

Editor's Picks

Welcome to EconoTimes